Aldeyra Therapeutics Inc (ALDX)

$2.18

$2.14

More risky doesn't have European approval like OTLK did

Huge insider buys last week

$1.94 on watch for FDA same story as OTLK

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of DirectorsJune 9, 2026 8:30 PM
Business Wire Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra’s board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience working with both publicly traded and venture-backed biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board. “We look forward to leveraging her expertise as Aldeyra continues to progress towards potential commercialization of therapies that address an unmet medical need.” Ms. Deptula-Hicks is a senior biotechnology executive with over 30 years of experience across public and private life science companies, spanning therapeutics, diagnostics, medical devices, and emerging healthcare technologies. She has held senior executive, chief financial officer, board roles, and has extensive experience supporting companies through initial public offerings, major capital raises, strategic partnerships, and M&A transactions. Ms. Deptula-Hicks currently serves as the acting Chief Financial Officer of Normunity Inc., a clinical-stage biotech company focused on novel therapies to treat cancer. Previously, she served as Chief Financial Officer of F-star Therapeutics, Inc. Ms. Deptula-Hicks holds an M.B.A. from Rivier University and a B.S. in Accounting from Southern New Hampshire University. “I look forward to supporting Aldeyra’ s Board and partnering with the leadership team to drive sustainable long-term growth,” Ms. Deptula-Hicks stated. About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the potential commercialization of the company’s therapies; the goals, opportunity, and potential for reproxalap. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” "could," “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “on track,” “scheduled,” “target,” “design,” “estimate,” “predict,” “contemplates,” “likely,” “potential,” “continue,” “ongoing,” “aim,” “plan,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra’s regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra’s ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra’s commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra’s ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra’s business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2025 and Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC website at https://www.sec.gov/. In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260609197950/en/ Investor & Media Contact
Laura Nichols
(781) 257-3060
investorrelations@aldeyra.com Original: Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDXMay 27, 2026 3:44 AM
PR Newswire (US) LOS ANGELES, May 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 3, 2023 to March 16, 2026DEADLINE: May 29, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Aldeyra's drug candidate, reproxalap generated inconsistent results in clinical trials. The Company's positive statements about its clinical trials were unreliable. Based on these facts, Aldeyra's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com View original content:https://www.prnewswire.com/news-releases/aldeyra-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--aldx-302782552.htmlSOURCE DJS Law Group LLP Original: Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX

ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law FirmMay 26, 2026 9:00 AM
PR Newswire (US) NEW YORK, May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/aldeyra-therapeutics-inc-loss-submission-form-2/?id=186863&from=4CLASS PERIOD: November 3, 2023 to March 16, 2026ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) The results of the reproxalap clinical trials were inconsistent; (2) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful; and (3) as a result, defendants' statements about Aldeyra's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.DEADLINE: May 29, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/aldeyra-therapeutics-inc-loss-submission-form-2/?id=186863&from=4NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALDX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 29, 2026. There is no cost or obligation to you to participate in this case.WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg @bback View original content to download multimedia:https://www.prnewswire.com/news-releases/aldx-shareholder-alert-aldeyra-therapeutics-inc-securities-class-action-lawsuit---investors-should-contact-the-gross-law-firm-302779782.htmlSOURCE The Gross Law Firm Original: ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Certified Misleading Filings: SueWallStApril 30, 2026 9:00 AM
PR Newswire (US)

Important Information Regarding Section 20(a) Individual Liability ClaimsNEW YORK, April 30, 2026 /PRNewswire/ -- SueWallSt alerts investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) of a pending securities class action naming three senior officers as individual defendants. Class Period: November 3, 2023 through March 16, 2026. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com | (888) SueWallSt.







ALDX shares collapsed $2.99 per share, a 70.7% single-day decline, closing at $1.24 on March 17, 2026 after the FDA issued a Complete Response Letter rejecting the Company's dry eye drug candidate reproxalap. The Court has set May 29, 2026 as the deadline to apply for lead plaintiff appointment.The Named Individual DefendantsTodd C. Brady, the Company's Chief Executive Officer throughout the entire Class Period, is named as a defendant. Michael Alferi, who became Head of Finance, principal financial officer, and principal accounting officer on August 31, 2024, is also named. Bruce M. Greenberg, who served as interim Chief Financial Officer from May 10, 2022 through August 31, 2024, is the third individual defendant. Each personally signed SEC filings containing the statements at issue.Section 20(a) Control Person FrameworkThe action contends these officers are liable as "controlling persons" under Section 20(a) of the Securities Exchange Act. As pleaded, each defendant participated in the operation and management of Aldeyra, directed the contents of reports and public filings, and exercised authority over the Company's public communications during the Class Period. Their positions gave them access to adverse non-public information about the reliability of reproxalap clinical trial data.Sarbanes-Oxley Certification ObligationsThe complaint charges that each filing officer certified the accuracy of Aldeyra's periodic reports under Sections 302 and 906 of the Sarbanes-Oxley Act. These certifications accompanied the 3Q23 Form 10-Q, the FY23, FY24, and FY25 Forms 10-K, each of which repeated claims that reproxalap had demonstrated "consistent" and "clinically relevant activity" across multiple trials. The FDA's March 2026 Complete Response Letter stated that trial results were inconsistent and that positive findings were unreliable.Alleged Control Person LiabilityBrady signed every SEC filing at issue across the full Class Period, from November 2023 through February 2026Greenberg co-signed the 3Q23 Report and the FY23 Report containing the earliest alleged misrepresentationsAlferi co-signed the FY24 and FY25 Reports that repeated materially identical language about reproxalap's trial performanceEach defendant had a duty to ensure Aldeyra's public statements were accurate and to correct statements that had become misleadingThe lawsuit asserts all three knew or recklessly disregarded that clinical trial results were inconsistent"Corporate officers have a duty to ensure their companies' public statements are accurate and complete. When officers personally certify SEC filings containing statements about clinical trial performance, they bear individual responsibility for the truthfulness of those representations." -- Joseph E. Levi, Esq.Submit your information to join the recovery or call Joseph E. Levi, Esq. at (888) SueWallSt.WHY SUEWALLST -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, SueWallSt is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.Frequently Asked Questions About the ALDX LawsuitQ: When did Aldeyra Therapeutics allegedly mislead investors? A: The class period runs from November 3, 2023 to March 16, 2026. The alleged fraud was revealed through the FDA's Complete Response Letter disclosed on March 17, 2026, causing a 70.7% stock decline.Q: Who are the defendants named in the ALDX lawsuit? A: The complaint names Aldeyra Therapeutics, Inc. and individual defendants including CEO Todd C. Brady, Head of Finance Michael Alferi, and former interim CFO Bruce M. Greenberg, each of whom signed SEC filings and certified financial disclosures under Sarbanes-Oxley.Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.Q: What if I already sold my ALDX shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.CONTACT:
SueWallSt.
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi @Icons1



View original content to download multimedia:https://www.prnewswire.com/news-releases/aldx-investor-alert-aldeyra-therapeutics-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-executives-allegedly-certified-misleading-filings-suewallst-302758262.htmlSOURCE SueWallSt.com

Original: ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Certified Misleading Filings: SueWallSt

Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDXApril 20, 2026 2:29 AM
PR Newswire (US)

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 3, 2023 to March 16, 2026DEADLINE: May 29, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Aldeyra's drug candidate, reproxalap generated inconsistent results in clinical trials. The Company's positive statements about its clinical trials were unreliable. Based on these facts, Aldeyra's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/aldeyra-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--aldx-302746804.htmlSOURCE DJS Law Group LLP

Original: Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX

ALDX.......................https://stockcharts.com/sc3/ui/?s=ALDX&p=w&b=5&g=0&id=p86431144783

Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDXApril 6, 2026 4:58 AM
PR Newswire (US)

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 3, 2023 to March 16, 2026DEADLINE: May 29, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Aldeyra's drug candidate, reproxalap generated inconsistent results in clinical trials. The Company's positive statements about its clinical trials were unreliable. Based on these facts, Aldeyra's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/aldeyra-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--aldx-302734473.htmlSOURCE DJS Law Group LLP

Original: Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX

Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDXApril 3, 2026 1:07 AM
PR Newswire (US)

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 3, 2023 to March 16, 2026
DEADLINE: May 29, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Aldeyra's drug candidate, reproxalap generated inconsistent results in clinical trials. The Company's positive statements about its clinical trials were unreliable. Based on these facts, Aldeyra's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
 Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/aldeyra-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--aldx-302733360.htmlSOURCE DJS Law Group LLP

Original: Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX

Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALDXApril 1, 2026 7:30 AM
Business WireThe DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 3, 2023 to March 16, 2026DEADLINE: May 29, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Aldeyra’s drug candidate, reproxalap generated inconsistent results in clinical trials. The Company’s positive statements about its clinical trials were unreliable. Based on these facts, Aldeyra’s public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.View source version on businesswire.com: https://www.businesswire.com/news/home/20260401684776/en/David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
Original: Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALDX

Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDXApril 1, 2026 2:47 AM
PR Newswire (US)

LOS ANGELES, April 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: November 3, 2023 to March 16, 2026DEADLINE: May 29, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Aldeyra's drug candidate, reproxalap generated inconsistent results in clinical trials. The Company's positive statements about its clinical trials were unreliable. Based on these facts, Aldeyra's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/aldeyra-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--aldx-302730835.htmlSOURCE DJS Law Group LLP

Original: Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX

ALDX..................................................https://stockcharts.com/sc3/ui/?s=ALDX&p=w&b=5&g=0&id=p86431144783

As of December 31, 2025, Aldeyra reported cash, cash equivalents, and marketable securities of $70 million, which are expected to support operations into 2028.

Aldeyra receives FDA rejection for dry eye treatment reproxalapMarch 17, 2026 10:14 AM
IH Market News
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its New Drug Application for reproxalap, a proposed treatment for dry eye disease.According to the FDA, there was “a lack of substantial evidence consisting of adequate and well-controlled investigations” demonstrating that the therapy would be effective under the proposed conditions of use. The agency added that the application “failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.”Regulators pointed to “inconsistency of study results,” which raised “serious concerns about the reliability and meaningfulness of the positive findings.” As a result, the FDA concluded that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.”The agency did not identify any safety or manufacturing issues in its review, in line with earlier assessments of reproxalap. Aldeyra noted that the FDA had provided draft labeling in December 2025 and again in March 2026, although final label negotiations were not completed.The FDA suggested that the company investigate the causes behind the unsuccessful trials and determine whether specific patient groups might benefit from reproxalap. However, the agency did not recommend conducting additional clinical studies or submitting further confirmatory evidence.Aldeyra said it does not currently intend to launch new clinical trials for the drug and plans to request a Type A meeting with the FDA to clarify what steps may be required to move the application forward. Under Prescription Drug User Fee Act guidelines, the meeting is expected to take place within 30 days of the request.As of December 31, 2025, the company reported approximately $70 million in cash, cash equivalents and marketable securities, which it said should be sufficient to fund operations through 2028.Based in Lexington, Massachusetts, Aldeyra Therapeutics focuses on developing treatments for immune-mediated conditions. Its pipeline includes RASP modulators as well as ADX-2191, a therapy being developed for retinal diseases.Aldeyra Therapeutics stock price

Original: Aldeyra receives FDA rejection for dry eye treatment reproxalap

Today they got their 2026 CRL - I believe this is number 3 for this drug candidate - I don't really follow them so know very little about it except they got knocked down over 70% this morning - A compelling area for serious gamblers IMO

Another CRL for Aldeyra yesterday highlighting that biotech companies can and do make use safe habor to make public claims about trial results that do not in the end hold true with regulatory access to and scrutiny of the data behind the claims.

Class Action Case Dismissed!

What do people think - 2nd time lucky with the PDUFA coming up 2nd April?

63% insty ownership and more increased than decreased positions - not that the 'smart' WS guys always get it right...

Oh that post didn't belong here, please delete!

ALDX under $7

My odds for clock stop one pass have gone down in a Bayesian way.

The hearing on the Motion to dismiss was on 7/24/24. Yes, all in the class case are waiting for the Court to render its opinion on the motion to dismiss.

The case has gone nowhere since Jul 24, 2024 "Motion Hearing AND Order on Motion to Dismiss" docket 42 - I believe dismissed, but haven't access to read the docket.

Current Aldeyra shareholders who have continuously held Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/ to learn more. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

Another big winner for me this year ICCM is next!

$ALDX

Sold half at around $5’ish for about 50% profit looking to buy back lower awaiting NDA filing and like decision dates for Reproxalap.

what your thoughts here for the future?

hi bro you know a good discord or web for parma and bio´s

when offering lol

No one happy here?

Will the dry eye confirmatory P3 trial prove successful this morning? Hard to call, but leaning towards yes.

ALDX under $4

NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS

Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.

Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.

Still progressing here. I think they have been prudent, of late... with the AbbVie option agreement for Reproxalap and other shots on goal without partners. There is certainly upside with continued clinical success. Any updated views on Aldeyra?

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

I added 3,500 shares on 10/16 as well below $1.80. I wish I leaned in more. I am a holder and still see long-term upside from here.

ALDX: Just crossed the (dangerous) 1.5-Hrs-Into-The-Open-Rubicon, and movin' UP from there!! (Not easy to do for ANY stock.)

Nice grab. It's good to be the early bird. I knew nothing about the company, just saw the news.

Me too, Dude. (And this Firm has worked on this drug for a long time; and that ain't NO 'small-potatoes' Company that just partnered with them either.)

Yep. I snatched up some of this pre-market.

ALDX: Could have a good day here; 'Dry Eye' syndrome afflicts MILLIONS worldwide!

I bought to average down today, it seems a sensible move.

With the pending readouts and relatively short trials that may provide additional support, I agree.

Also, the company has some breathing room with > $2 per share in cash after all liabilities as of 6/30 and only burning ~ $0.20 per share quarterly.

The current sub $2 share price looks attractive to me.

Ouch indeed, but it isn’t over for dry eye and we are expecting one other different P3 indication readout this year.

Ouch

A not so great day yesterday for $ALDX.

Small potential indication costing the 25% run up we have in expectation of H2 events.

It isn’t over for ADX-2191 yet though…